Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10004061 | 1.00 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL857081 | 0.94 | ELANE (0.48) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL4273425 | 0.92 | CA1 (0.50) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL4277332 | 0.92 | MEN1 (0.43) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL1808359 | 0.92 | CA1 (0.50) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL1807712 | 0.91 | ELANE (0.42) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL10004179 | 0.89 | NPC1 (0.49) | NPC1RAB9AELANECA1CA2 | |
| SCHEMBL1809484 | 0.88 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL4634185 | 0.88 | NPC1 (0.44) | NPC1RAB9AMEN1KMT2AELANE | |
| SCHEMBL4273322 | 0.87 | PPARG (0.45) | NPC1RAB9AMEN1KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928475-B1 | ANTIVIRAL PHOSPHORAMIDATES OF 4'-C-AZIDO-SUBSTITUTED PRONUCLEOTIDES | RIBOSCIENCE LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| WO-2012103990-A1 | PHOSPHORAMIDATES OF MONOSACCHARIDES | BIOIBERICA, S.A. (ES) | 2012-08-09 | — | — | WO | disclosed |
| EP-2471802-A1 | Phosphoramidates of monosaccharides | Bioiberica, S.A. (ES) | 2012-07-04 | — | — | EP | disclosed |
| US-8119779-B2 | Phosphoramidate derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED | 2012-02-21 | — | — | US | disclosed |
| US-7608599-B2 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070275910-A1 | Phosphoramidate Derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2007-11-29 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | NPC1 1467/4885RAB9A 165/4885MEN1 3374/4885 |
| US-20070275910-A1 | Phosphoramidate Derivatives | HRH4, HRH3, NR1H4 | NPC1 3445/4885RAB9A 4185/4885MEN1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.